Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /  Forum  /  BioPharma  /  INSM - Insmed - Deel 15

BioPharma« Terug naar discussie overzicht

INSM - Insmed - Deel 15

Volgen
2.002 Posts
Pagina: «« 1 ... 40 41 42 43 44 ... 101 »» | Laatste | Omlaag ↓
  5. [verwijderd] 18 juli 2007 14:20
    www.biosimilarstoday.com/#Program

    Wellicht zal de small biotech rep, Dr. Allan zijn!

    Kijk wat er gebeurt, indien een organisatie zich NIET goed voorbereid op de komst van Generics...

    Pfizer winst met 50% gehalveerd door GENERICS!!
    tinyurl.com/2zon7g

    Pfizer's profit plunges on generic competition
    Drugmaker reiterates 2007 financial forecast
    By Val Brickates Kennedy, MarketWatch
    Last Update: 7:54 AM ET Jul 18, 2007

    BOSTON (MarketWatch) -- Pfizer Inc.'s second-quarter earnings fell dramatically, due largely to generic competition for its top-selling Zoloft, Norvasc and Lipitor drugs, financial results showed Wednesday.
    New York-based Pfizer reported a net profit of $1.27 billion, or 18 cents a share, compared with $2.42 billion, or 33 cents a share, for the same quarter last year.
    Excluding various charges, Pfizer would have posted adjusted earnings of 42 cents a share for the latest quarter, with the world's largest drugmaker generating revenue of $11.08 billion, down 6%.
    Analysts polled by Thomson Financial had, on average, pegged Pfizer's profit at 50 cents a share on revenue of $11.42 billion.
    "There's no question that we faced difficult challenges in the second quarter," said Chief Executive Jeffrey Kindler in a statement. He cited the loss of U.S. exclusivity for Zoloft and Norvasc as well as the timing of some expenses and Lipitor's performance in the U.S.

    Nonetheless, "we're still on track to meet our previously announced 2007 and 2008 revenue and adjusted diluted EPS goals," Kindler said.
    Specifically, the drugmaker reiterated its prior 2007 financial forecast calling for revenue of between $47 billion and $48 billion, with earnings per share coming in between $1.30 and $1.41. Adjusted earnings per share should be between in a range of $2.08 and $2.15.
    Pfizer's top line has been under considerable pressure in recent quarters because of the loss of patent protection for several of its once-hot products, such as Zoloft, Zithromax and, most recently, Norvasc.
    Indeed, Norvasc's second-quarter sales fell 45% to $642 million. Prior to losing its patent protection, Norvasc was Pfizer's second best-selling product.
    Pfizer's Lipitor, the world's best-selling drug, has also faced increased generic competition now that rival cholesterol-lowering pharmaceuticals, such as Pravachol from Bristol-Myers Squibb Co. and Zocor from Merck & Co., have lost their patent protections.
    Quarterly sales of Lipitor fell 13% to $2.7 billion. U.S. sales got hit especially hard, tumbling 25%.
    The company said it now sees 2007 sales of Lipitor being either flat or 5% lower than last year.
    In a recent note, Banc of America analysts said they were looking for Lipitor's quarterly sales to be about $3.1 billion, or 1% lower than in the 2006 second quarter.
    Pfizer added that it has repurchased $5 billion of its common shares during the first half of 2007 and plans to buy back an additional $5 billion in the second half.
    Shares of Pfizer, part of the Dow Jones Industrial Average, lost 12 cents to end Tuesday's trading at $25.96. End of Story
    Val Brickates Kennedy is a reporter for MarketWatch in Boston.

    Mooie tijden komen eraan! Laat die shorts de PPS maar naar beneden drijven; maatregelen mijnerzijds zijn genomen!
    Voor't einde van't jaar wordt't groot feest!

    Geluk, F.
    (..Mijn dochter heeft met PFE te doen; weet dat INSM het beter zal doen...zij ook!)
  7. ludwig mack 18 juli 2007 16:05
    Last Trade: 0.7300
    Trade Time: 9:39AM ET
    Change: 0.0130 (1.75%)
    Prev Close: 0.74
    Open: 0.71
    Bid: 0.7211 x 900
    Ask: 0.7299 x 500
    1y Target Est: 2.00

    Day's Range: 0.7100 - 0.7400
    52wk Range: 0.68 - 1.98
    Volume: 134,210
    Avg Vol (3m): 1,733,030
    Market Cap: 73.97M
    P/E (ttm): N/A
    EPS (ttm): -0.53
    Div & Yield: N/A (N/A)

  10. ludwig mack 18 juli 2007 22:19
    Last Trade: 0.7221
    Trade Time: 4:00PM ET
    Change: 0.0209 (2.81%)
    Prev Close: 0.743
    Open: 0.71
    Bid: 0.6920 x 7000
    Ask: 0.7395 x 2100
    1y Target Est: 2.00

    Day's Range: 0.7100 - 0.7400
    52wk Range: 0.68 - 1.98
    Volume: 526,515
    Avg Vol (3m): 1,733,030
    Market Cap: 73.17M
    P/E (ttm): N/A
    EPS (ttm): -0.526
    Div & Yield: N/A (N/A)

  14. ludwig mack 19 juli 2007 22:22
    Last Trade: 0.7600
    Trade Time: 3:59PM ET
    Change: 0.0379 (5.25%)
    Prev Close: 0.72
    Open: 0.72
    Bid: 0.7500 x 600
    Ask: 0.7700 x 2500
    1y Target Est: 2.00

    Day's Range: 0.7200 - 0.7600
    52wk Range: 0.68 - 1.98
    Volume: 1,032,952
    Avg Vol (3m): 1,736,490
    Market Cap: 77.01M
    P/E (ttm): N/A
    EPS (ttm): -0.53
    Div & Yield: N/A (N/A)

  16. ludwig mack 21 juli 2007 01:20
    Last Trade: 0.74
    Trade Time: 3:59PM ET
    Change: 0.02 (2.50%)
    Prev Close: 0.76
    Open: 0.76
    Bid: 0.72 x 500
    Ask: 0.77 x 5000
    1y Target Est: 2.00

    Day's Range: 0.73 - 0.77
    52wk Range: 0.68 - 1.98
    Volume: 463,559
    Avg Vol (3m): 1,978,310
    Market Cap: 75.08M
    P/E (ttm): N/A
    EPS (ttm): -0.526
    Div & Yield: N/A (N/A)

  17. ludwig mack 23 juli 2007 17:36
    Last Trade: 0.7200
    Trade Time: 11:19AM ET
    Change: 0.0210 (2.83%)
    Prev Close: 0.74
    Open: 0.75
    Bid: 0.7224 x 3500
    Ask: 0.7225 x 3000
    1y Target Est: 2.00

    Day's Range: 0.7150 - 0.7517
    52wk Range: 0.68 - 1.98
    Volume: 243,016
    Avg Vol (3m): 1,675,360
    Market Cap: 72.96M
    P/E (ttm): N/A
    EPS (ttm): -0.53
    Div & Yield: N/A (N/A)

  19. ludwig mack 23 juli 2007 22:20
    Last Trade: 0.7153
    Trade Time: 3:59PM ET
    Change: 0.0257 (3.47%)
    Prev Close: 0.741
    Open: 0.75
    Bid: 0.7000 x 1500
    Ask: 0.7200 x 700
    1y Target Est: 2.00

    Day's Range: 0.7150 - 0.7517
    52wk Range: 0.68 - 1.98
    Volume: 619,037
    Avg Vol (3m): 1,954,330
    Market Cap: 72.48M
    P/E (ttm): N/A
    EPS (ttm): -0.526
    Div & Yield: N/A (N/A)

2.002 Posts
Pagina: «« 1 ... 40 41 42 43 44 ... 101 »» | Laatste |Omhoog ↑

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
Basic-Fit 25,300 +1,30 +5,42%
AMG Critical Materials N.V. 17,000 +0,78 +4,81%
ASML 657,800 +23,60 +3,72%
BESI 104,600 +3,70 +3,67%
TomTom 5,175 +0,16 +3,19%
FASTNED 22,400 +0,65 +2,99%
RANDSTAD NV 43,780 +1,10 +2,58%
PROSUS 39,455 +0,95 +2,48%
Fugro 21,820 +0,48 +2,25%
ArcelorMittal 22,600 +0,49 +2,22%
Alfen N.V. 12,305 +0,27 +2,20%
Kendrion 11,580 +0,24 +2,12%
Pharming 0,812 +0,02 +2,07%
SIGNIFY NV 22,560 +0,40 +1,81%
Aperam 26,060 +0,46 +1,80%
PostNL 1,138 +0,02 +1,70%
Akzo Nobel 63,840 +1,06 +1,69%
ABN AMRO BANK N.V. 15,630 +0,25 +1,59%
NX FILTRATION 4,655 +0,07 +1,53%
ASMI 520,600 +7,20 +1,40%
Aegon 5,948 +0,07 +1,16%
Wereldhave 15,000 +0,16 +1,08%
ALLFUNDS GROUP 5,265 +0,05 +1,06%
Corbion 25,300 +0,26 +1,04%
AALBERTS NV 33,860 +0,34 +1,01%
TKH 38,120 +0,32 +0,85%
B&S Group SA 4,880 +0,04 +0,83%
INPOST 18,590 +0,12 +0,65%
Flow Traders 21,740 +0,14 +0,65%
SBM Offshore 17,130 +0,10 +0,59%
EBUSCO HOLDING 0,700 +0,00 +0,58%
CM.COM 7,020 +0,04 +0,57%
Brunel 8,870 +0,05 +0,57%
ASCX 1.268,66 +6,54 +0,52%
Galapagos 28,000 +0,12 +0,43%
Ahold Delhaize 30,630 +0,12 +0,39%
HEIJMANS KON 26,250 +0,10 +0,38%
JDE PEET'S 18,820 +0,07 +0,37%
Van Lanschot Kempen NV 44,850 +0,15 +0,34%
Heineken 78,480 +0,26 +0,33%
AEX 901,24 +2,61 +0,29%
AMX 899,21 +2,42 +0,27%
BAM 4,686 +0,01 +0,26%
NSI 20,200 +0,05 +0,25%
ACOMO 17,340 +0,04 +0,23%
DSM FIRMENICH AG 116,100 +0,25 +0,22%
Vastned 24,500 +0,05 +0,20%
EXOR NV 98,750 +0,15 +0,15%
AZERION 1,432 +0,00 +0,14%
Air France-KLM 9,094 +0,01 +0,13%
ADYEN NV 1.393,800 +1,80 +0,13%
ASR Nederland 45,100 +0,04 +0,09%
SHELL PLC 30,970 +0,01 +0,03%
ING 15,986 +0,00 +0,01%
Arcadis 66,050 0,00 0,00%
Fagron 18,740 0,00 0,00%
IMCD 151,800 0,00 0,00%
JUST EAT TAKEAWAY 10,955 0,00 0,00%
Nedap N.V. 56,400 0,00 0,00%
OCI 25,050 0,00 0,00%
Sif Holding 14,200 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
WDP 22,640 -0,88 -3,74%
Avantium 2,565 -0,08 -3,02%
RELX 44,160 -0,76 -1,69%
ForFarmers 3,235 -0,05 -1,52%
Wolters Kluwer 158,800 -2,15 -1,34%
CTP 16,760 -0,20 -1,18%
UNILEVER PLC 57,660 -0,68 -1,17%
THEON INTERNAT 9,220 -0,09 -0,97%
Eurocommercial Properties 24,400 -0,20 -0,81%
KPN 3,776 -0,02 -0,53%
RENEWI 7,560 -0,04 -0,53%
Sligro 12,280 -0,06 -0,49%
UMG 24,060 -0,04 -0,17%
Accsys 0,613 0,00 -0,16%
NN Group 46,440 -0,06 -0,13%
Vopak 42,040 -0,02 -0,05%
Philips Koninklijke 29,480 -0,01 -0,03%
vlag naam koers verschil relatief verschil
AEX 901,16 +2,53 +0,28%
AEX GR 3.522,74 +10,47 +0,30%
Germany40^ 19.636,30 +52,91 +0,27%
FTSE 100 8.354,57 -30,56 -0,36%
EURO50 4.978,07 +32,93 +0,67%
US30^ 43.217,30 -36,50 -0,08%
Nasd100^ 20.342,60 +148,80 +0,74%
US500^ 5.862,76 +20,43 +0,35%
Japan225^ 39.183,60 -5,60 -0,01%
VD-NEW 16,59 -0,54 -3,17%
#/^ Index indications calculated real time, zie disclaimer